Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting

BOSTON–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$GMDAlt;/agt;–Gamida
Cell Ltd.
(Nasdaq: GMDA), a leading cellular and immune therapeutics
company, today announced that it will host a conference call and webcast
on Thursday, February 21, 2019, at 8:00 a.m. ET to review the data from
its NAM-NK and NiCord® programs being presented at the 2019
Transplantation & Cellular Therapy (TCT) Meetings of American Society
for Blood and Marrow Transplantation (ASBMT) and Center for
International Blood and Marrow Transplant Research (CIBMTR). The meeting
is taking place in Houston, Texas, February 20 – 24.

A live webcast of the conference call can be accessed in the Investors
section of Gamida Cell’s website at
To participate in the conference call, please dial 1-866-930-5560
(domestic) or 1-409-216-0605 (international) five minutes prior to start
time. The conference ID number is 9462948. An archived version of the
webcast will be available on Gamida Cell’s website for 30 days.

Details about the presentations are as follows:

Time: Wednesday, February 20, 2019, 6:45 p.m. – 7:45 p.m. CT
(poster presentation)
Title: First-in-Human Phase I Study of
Nicotinamide-Expanded Related Donor Natural Killer Cells for the
Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple
Poster Number: 242
Lead Author: Veronika
Bachanova, M.D., Ph.D., associate professor of medicine, division of
hematology, oncology and transplantation, University of Minnesota
George R. Brown Convention Center, Level 3, Hall B

Time: Wednesday, February 20, 2019, 6:45 p.m. – 7:45 p.m. CT
(poster presentation)
Title: Ex Vivo Nicotinamide-Expanded
(NAM-Expanded) Unrelated Cord Blood Transplantation (UCB) for Refractory
Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune
Poster Number: 295
Lead Author: Joseph
Clara, M.D., Hematology Branch, National Heart, Lung, and Blood
Location: George R. Brown Convention Center, Level
3, Hall B

Time: Saturday, February 23, 2019, 4:45 p.m. – 5:00 p.m. CT (oral
Title: Rapid and Robust CD4+ and CD8+ T-, NK-,
B-Cell, Dendritic Cell, and Monocyte Reconstitution after
Nicotinamide-Expanded Cord Blood Transplantation
Lead Author: Jaap-Jan Boelens, M.D., Ph.D.,
Chief, Pediatric Stem Cell Transplantation and Cellular Therapies
Service, Memorial Sloan Kettering Cancer Center
Location: Hilton
Americas Houston, Grand Ballroom G

Abstracts are available on the 2019 TCT
Meetings of ASBMT and CIBMTR website.

About NAM-NK
Gamida Cell applied the capabilities of its
NAM-based cell expansion technology to highly functional NK cells to
develop NAM-NK, an innate immunotherapy for the treatment of hematologic
and solid tumors in combination with standard of care antibody
therapies. NAM-NK addresses key limitations of NK cells by increasing
the cytotoxicity and in vivo retention and proliferation in the
bone marrow and lymphoid organs of NK cells expanded in culture. NAM-NK
is in Phase 1 development through an investigator-sponsored study in
patients with refractory non-Hodgkin lymphoma and multiple myeloma.1

About NiCord
NiCord, the company’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has been
granted Breakthrough Therapy designation by the U.S. Food and Drug
Administration, making it the first bone marrow transplant alternative
to receive this designation. It has also received U.S. and EU orphan
drug designation. A Phase 3 clinical study evaluating NiCord in patients
with leukemia and lymphoma is ongoing in the United States, Europe and
Asia.2 NiCord is also being evaluated in a Phase 1/2 clinical
study in patients with severe aplastic anemia.3 The aplastic
anemia investigational new drug application is currently filed with the
FDA under the brand name CordIn®, which is the same
investigational development candidate as NiCord. For more information on
clinical trials of NiCord, please visit

NAM-NK and NiCord are investigational therapies, and their safety and
efficacy have not been evaluated by the U.S. Food and Drug
Administration or any other health authority.

About Gamida Cell
Gamida Cell is a clinical stage
biopharmaceutical company leveraging its proprietary technology to
develop cell therapies that are designed to cure cancer and rare,
serious hematologic diseases. The company is leveraging its
nicotinamide-, or NAM-, based cell expansion technology to develop a
pipeline of products designed to address the limitations of cell

Cautionary Note Regarding Forward Looking Statements
press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the presentations of data related to the Phase
1 study of NAM-NK, the Phase 1/2 study of NiCord for the treatment of
hematologic malignancies, and the Phase 1/2 study of NiCord for the
treatment of severe aplastic anemia, which statements are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to the scope, progress and expansion of Gamida Cell’s studies.
In light of these risks and uncertainties, and other risks and
uncertainties that are described in the Risk Factors section of our
Registration Statement on Form F-1 filed with the SEC on September 28,
2018, and other filings that Gamida Cell makes with the SEC from time to
time (which are available at,
the events and circumstances discussed in such forward-looking
statements may not occur, and Gamida Cell’s actual results could differ
materially and adversely from those anticipated or implied thereby. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Gamida Cell as of the
date of this release.

1 identifier NCT03019666.
2 identifier NCT02730299.
identifier NCT03173937.


Jaren Irene Madden


Krystle Gibbs

error: Content is protected !!